Onxeo Adjusts Direction With Acquisition Of DNA-Repair Interference Platform
This article was originally published in The Pink Sheet Daily
Firm that was focused on technology to reformulate old drugs gains platform for novel drugs that will induce cell death in orphan oncology indications.
You may also be interested in...
Rather than rail at China, senators explored causes and corrective actions for drug shortages that are closer to home.
Study commissioned by the PhRMA underscores concerns about how the coronavirus has disrupted use of physician-administered drugs.
At ASCO symposium on cancer care during the pandemic, NCI Director Ned Sharpless notes trial accrual at NCI's National Clinical Trials Network dropped by half in March and April.